Related Experiment Video
Updated: Jul 6, 2025

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells
Published on: August 25, 2021
To Investigate Growth Factor Receptor Targets and Generate Cancer Targeting Inhibitors
Debroop Basu1, Riya Pal2, Maitrayee Sarkar1
1Cell and Developmental Biology Special, Department of Zoology, University of Kalyani, Kalyani, Nadia, 741235, India.
Abstract:
Receptor tyrosine kinase (RTK) regulates multiple pathways, including Mitogenactivated protein kinases (MAPKs), PI3/AKT, JAK/STAT pathway, etc. which has a significant role in the progression and metastasis of tumor. As RTK activation regulates numerous essential bodily processes, including cell proliferation and division, RTK dysregulation has been identified in many types of cancers. Targeting RTK is a significant challenge in cancer due to the abnormal upregulation and downregulation of RTK receptors subfamily EGFR, FGFR, PDGFR, VEGFR, and HGFR in the progression of cancer, which is governed by multiple RTK receptor signalling pathways and impacts treatment response and disease progression. In this review, an extensive focus has been carried out on the normal and abnormal signalling pathways of EGFR, FGFR, PDGFR, VEGFR, and HGFR and their association with cancer initiation and progression. These are explored as potential therapeutic cancer targets and therefore, the inhibitors were evaluated alone and merged with additional therapies in clinical trials aimed at combating global cancer.
Insights
Receptor tyrosine kinases (RTKs) are crucial for cell growth but their dysregulation drives cancer. This review examines RTK signaling pathways and their therapeutic targeting in cancer treatment.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Receptor tyrosine kinases (RTKs) regulate vital cellular processes like proliferation and division.
- Dysregulation of RTK signaling is implicated in the initiation and progression of various cancers.
- Specific RTK subfamilies (EGFR, FGFR, PDGFR, VEGFR, HGFR) are frequently altered in tumors.
Conclusions:
- Targeting RTKs is a critical strategy in cancer therapy.
- Understanding RTK signaling is essential for developing effective cancer treatments.
- Further clinical evaluation of RTK inhibitors is warranted.
More Related Videos
07:48Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures
Published on: December 26, 2016
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Mitogens and the Cell Cycle
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Treatment Resistant Cancers
Tumor Immunotherapy